Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma

Journal of Immunotherapy

Volumn 37, Issue 6, 2014, Pages 348-350

  Du Rusquec, Pauline ^a   Saint Jean, Melanie ^a,b   Brocard, Anabelle ^a,b   Peuvrel, Lucie ^a,b   Khammari, Amir ^a,b   Quéreux, Gaelle ^a,b   Dréno, Brigitte ^a,b  

^a Departments of Dermato Oncology   (France)

^b HÔTEL DIEU   (France)

Author keywords

ipilimumab; melanoma; pancytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; ERYTHROPOIETIN; IMMUNOGLOBULIN; IPILIMUMAB; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN; MONOCLONAL ANTIBODY;

AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CHEMOTHERAPY INDUCED ANEMIA; DRUG MEGADOSE; ENTEROBACTER CLOACAE; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INGUINAL LYMPH NODE; LABORATORY TEST; LEUKOCYTE COUNT; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL HISTORY; METASTATIC MELANOMA; MONOTHERAPY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PANCYTOPENIA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RAOUELTELLA PLANTICOLA; RETICULOCYTE COUNT; SEPTIC SHOCK; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT RESPONSE; ADVERSE EFFECTS; AUTOIMMUNE DISEASES; COMPLICATION; CONVALESCENCE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METASTASIS; PHYSIOLOGIC MONITORING; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; LEUKOCYTE COUNT; MELANOMA; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; PANCYTOPENIA; RECOVERY OF FUNCTION; SKIN NEOPLASMS;

EID: 84902196572     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000041     Document Type: Article

References (9)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364: 2517-2526.
3. Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Manag Res. 2012;4: 1-8.
4. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12: 864-872.
5. Di Giacomo AM, Danielli R, Calabro L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother. 2011;60: 467-477.
6. Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009;32: 322-324.
7. Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009;58: 1351-1353.
8. Duquenne M, Lakomsky D, Humbert JC, et al. Pancytopenia resolved by the treatment of hyperthyroidism. Presse Med. 1995;24: 807-810.
9. Shaw B, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. Clin Lab Haematol. 2002;24: 385-387.